No black box warning on record for Arformoterol Tartrate Inhalation

As of the latest FDA labeling reviewed, Arformoterol Tartrate Inhalation (ARFORMOTEROL TARTRATE INHALATION) does not carry a black box warning. Standard warnings and precautions still apply — see the full Arformoterol Tartrate Inhalation medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • LABA as monotherapy (without an inhaled corticosteroid) for asthma increases the risk of serious asthma-related events. ( 5.1 ) • Do not initiate arformoterol tartrate inhalation solution in acutely deteriorating patients. ( 5.2 ) • Do not use for relief of acute symptoms. Concomitant short-acting beta 2 -agonists can be used as needed for acute relief. ( 5.2 ) • Do no

No black box warning on record for Arformoterol Tartrate Inhalation

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • LABA as monotherapy (without an inhaled corticosteroid) for asthma increases the risk of serious asthma-related events. ( 5.1 ) • Do not initiate arformoterol tartrate inhalation solution in acutely deteriorating patients. ( 5.2 ) • Do not use for relief of acute symptoms. Concomitant short-acting beta 2 -agonists can be used as needed for acute relief. ( 5.2 ) • Do no

Arformoterol Tartrate Inhalation Black Box Warning

No black box warning on record for Arformoterol Tartrate Inhalation

Other warnings & precautions

Arformoterol Tartrate Inhalation Black Box Warning

No black box warning on record for Arformoterol Tartrate Inhalation

Other warnings & precautions